Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maze TherapeuticsMAZE +0.81%16 EV-to-EBITDA is -9.05 as of Aug. 12, 2026. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 398 Biotechnology companies, Maze Therapeutics ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Maze Therapeutics's enterprise value is $1,232.50 Mil.
Maze Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-136.26 Mil. Therefore, Maze Therapeutics's EV-to-EBITDA for today is -9.05.
The historical rank and industry rank for Maze Therapeutics's EV-to-EBITDA or its related term are showing as below:
MAZE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.28 Med: -8.41 Max: 8.67
Current: -9.05
During the past 4 years, the highest EV-to-EBITDA of Maze Therapeutics was 8.67. The lowest was -16.28. And the median was -8.41.
MAZE's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs MAZE: -9.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Maze Therapeutics's PE Ratio (TTM) for today is calculated as:
Maze Therapeutics's share price for today is $27.53.
Maze Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Maze Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maze Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's EV-to-EBITDA falls into.
Maze Therapeutics's current Enterprise Value is $1,232.50 Mil.
Maze Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-136.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maze Therapeutics (MAZE) has a EV-to-EBITDA of -9.05 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maze Therapeutics. According to the industry distribution chart, Maze Therapeutics ranks #999999 out of 398 companies in the Biotechnology industry.
Is Maze Therapeutics' EV-to-EBITDA too high?
Maze Therapeutics' current EV-to-EBITDA is -9.05. Based on the distribution chart, Maze Therapeutics ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' EV-to-EBITDA compare to NTLA and RXRX?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #999999 out of 398 companies for EV-to-EBITDA. This places Maze Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maze Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current EV-to-EBITDA is -9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current EV-to-EBITDA of -9.05. The current EV-to-EBITDA is -9.05. Maze Therapeutics' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current EV-to-EBITDA is -9.05 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score
Get the complete analysis for MAZE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
